OBIMF (Ondine Biomedical) Other Stockholders Equity: $21.92 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBIMF Ondine Biomedical Inc OBIMF
15 GF Score
Price $0.25
GF Value $0.20
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Ondine Biomedical Other Stockholders Equity?

Ondine Biomedical OBIMF 15 Other Stockholders Equity is $21.92 Mil as of Dec. 2025. GuruFocus rates OBIMF with a GF Score™ of 15/100 and a GF Value™ of $0.20 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Ondine Biomedical's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $21.92 Mil.

Ondine Biomedical's quarterly Other Stockholders Equity increased from Dec. 2024 ($20.85 Mil) to Jun. 2025 ($21.78 Mil) and increased from Jun. 2025 ($21.78 Mil) to Dec. 2025 ($21.92 Mil).

Ondine Biomedical's annual Other Stockholders Equity declined from Dec. 2023 ($21.45 Mil) to Dec. 2024 ($20.85 Mil) but then increased from Dec. 2024 ($20.85 Mil) to Dec. 2025 ($21.92 Mil).

Ondine Biomedical Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Ondine Biomedical's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical Other Stockholders Equity Chart

Ondine Biomedical Annual Data
Trend Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.22 21.00 21.45 20.85 21.92

Ondine Biomedical Semi-Annual Data
Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.45 21.37 20.85 21.78 21.92
OBIMF
15GF Score
Ondine Biomedical Inc OBIMF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ondine Biomedical Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $21.92 Mil mean?
Ondine Biomedical (OBIMF) has a Other Stockholders Equity of $21.92 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Ondine Biomedical and its competitors.
Is Ondine Biomedical's Other Stockholders Equity too high?
Ondine Biomedical's current Other Stockholders Equity is $21.92 Mil. Overall, Ondine Biomedical has a GF Score™ of 15/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's Other Stockholders Equity compare to VRTX and REGN?
Ondine Biomedical's Other Stockholders Equity of $21.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Ondine Biomedical and its competitors. Ondine Biomedical's current Other Stockholders Equity is $21.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (OBIMF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $0.25 — trading 25% above its estimated fair value. The current Other Stockholders Equity is $21.92 Mil. Ondine Biomedical's overall GF Score™ is 15/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Ondine Biomedical (OBIMF), the current Other Stockholders Equity is $21.92 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ondine Biomedical (OBIMF) Overvalued in 2026?

Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued. The current stock price of $0.25 is trading 25% above its estimated GF Value™ of $0.20. GuruFocus considers Ondine Biomedical to be Modestly Overvalued.

Key valuation signals for OBIMF:

  • Other Stockholders Equity: $21.92 Mil
  • GF Value™: $0.20 vs. price of $0.25 (25% above fair value)
  • GF Score™: 15/100 with 9 warning signs

No single metric tells the full story. See the OBIMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ondine Biomedical Business Description

Other Exchanges OBI:UKVF5:Germany
Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
15GF Score

Get the complete analysis for OBIMF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.20
GF Value